Equities

Aegirbio AB

Aegirbio AB

Actions
  • Price (SEK)5.19
  • Today's Change-0.088 / -1.67%
  • Shares traded133.02k
  • 1 Year change-96.86%
  • Beta--
Data delayed at least 15 minutes, as of Sep 30 2022 17:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

  • Revenue in SEK (TTM)8.07m
  • Net income in SEK-99.56m
  • Incorporated--
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Peptonic Medical AB31.19m-74.91m78.16m----1.25--2.51-0.3837-0.38370.15580.25710.29361.092.46---70.50-38.78-88.68-45.5562.09---240.16-223.580.7398-66.680.1069---10.10---115.39---16.66--
Carbiotix AB (publ)158.96k-11.56m78.96m----2.73--496.71-0.8847-0.88470.01222.020.0053--8.64---38.69---41.57--1,379.37---7,274.50-----11,798.530.00--216.80---75.07------
Calmark Sweden AB225.33k-28.88m79.38m----0.8142--352.28-0.8828-0.88280.00691.990.003-0.051710.18---38.73-19.25-42.04-20.86169.62---12,817.95-22,233.751.31-1,454.780.0013-------106.10--36.81--
Prolight Diagnostics AB (publ)0.00-7.95m86.85m----0.2863-----0.0533-0.05330.001.090.00-------4.96-5.03-5.05-5.18------------0.00-------59.41---52.37--
Veg of Lund AB (publ)3.44m-45.08m88.68m--------25.79-3.97-3.970.2996-0.28330.3001.033.09---393.31-138.73-13,028.61-212.6421.6334.56-1,310.82-936.480.4755-309.891.83--118.61---29.46------
Toleranzia AB0.00-7.54m99.50m----0.8046-----0.0725-0.07250.001.120.00-------7.56-12.63-7.92-13.30------------0.0068-------27.68--55.48--
Wntresearch AB0.00-38.28m109.25m2.00--4.15-----0.2671-0.26710.000.19740.00-------76.32-91.88-84.24-108.26------------0.00-------65.89------
Xintela AB0.00-74.67m109.34m-----------0.4982-0.49820.00-0.22020.00-------239.86-119.65-2,878.64-180.99-------12,122.000.0812-32.56---------19.76--27.36--
Bioextrax AB publ478.23k-13.74m109.35m----5.51--228.65-0.9001-0.90010.03151.270.0238--2.85---68.43---84.55---109.43---2,872.72-----8,749.480.00--1,166.12---89.02------
AegirBio AB8.07m-99.56m111.78m1.00--0.3509--13.86-5.22-5.220.390514.970.02030.21670.3217---25.09---27.36--39.21---1,234.28--2.46-7.560.0076--------------
AroCell AB (publ)26.04m-68.60m115.07m----0.46--4.42-0.4906-0.49060.16651.090.16677.194.71---44.48-32.88-47.33-35.44-34.16-37.34-266.79-966.135.87-69,476.000.00--14,180.95194.00-107.99---47.95--
Coegin Pharma AB0.00-29.14m118.03m----4.16-----0.044-0.0440.000.04090.00-------91.27---99.46-------------88.670.00------44.10------
Isofol Medical AB (publ)17.89m-214.10m130.34m14.00--0.6025--7.28-4.34-4.340.14241.340.0417--1.541,192,800.00-49.89-61.04-66.06-74.66-----1,196.64-1,186.01----0.0012---39.63---5.96------
New Nordic Healthbrands AB499.95m-4.30m131.34m37.00--1.21--0.2627-0.6933-0.693380.7017.492.064.314.08---1.7713.05-3.6625.3611.8217.56-0.85915.290.9236-0.84050.285938.8714.3910.9819.9217.3535.3325.59
Nordic Nanovector ASA0.00-441.52m141.61m40.00--0.7628-----4.20-4.200.001.570.00----0.00-107.68-69.82-153.00-88.28-------636,940.80----0.00-------5.81---29.60--
Annexin Pharmaceuticals AB (publ)0.00-45.04m145.85m4.00--4.21-----0.4445-0.44450.000.2240.00-------154.82-118.13-182.46-143.44-----------23.200.00-------17.86------
Data as of Sep 30 2022. Currency figures normalised to Aegirbio AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.38%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 08 Sep 202280.69k0.38%
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.